Teacher Retirement System of Texas Cuts Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teacher Retirement System of Texas reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 341,487 shares of the company's stock after selling 46,851 shares during the quarter. Teacher Retirement System of Texas' holdings in Teva Pharmaceutical Industries were worth $3,565,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of TEVA. Sound Shore Management Inc CT bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $80,791,000. FMR LLC lifted its position in Teva Pharmaceutical Industries by 3,553.8% in the third quarter. FMR LLC now owns 2,564,339 shares of the company's stock worth $26,156,000 after buying an additional 2,494,156 shares during the last quarter. Meitav Investment House Ltd. boosted its stake in Teva Pharmaceutical Industries by 82.8% during the fourth quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company's stock worth $44,914,000 after buying an additional 1,950,500 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 6.9% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company's stock valued at $301,920,000 after acquiring an additional 1,860,000 shares during the last quarter. Finally, AustralianSuper Pty Ltd raised its stake in shares of Teva Pharmaceutical Industries by 18.8% in the fourth quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company's stock valued at $94,368,000 after acquiring an additional 1,431,671 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEVA has been the topic of several analyst reports. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target on the stock in a report on Friday, March 8th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and upped their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 10th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the company an "overweight" rating in a research note on Thursday, May 9th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average price target of $14.22.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Vikki L. Conway sold 15,219 shares of the company's stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the sale, the chief executive officer now owns 87,125 shares of the company's stock, valued at $1,145,693.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 374,191 shares of company stock valued at $4,994,586. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Stock Down 1.8 %

Shares of NYSE TEVA traded down $0.31 during mid-day trading on Wednesday, reaching $16.78. 12,697,632 shares of the company were exchanged, compared to its average volume of 11,031,092. The firm has a 50-day moving average of $13.95 and a 200 day moving average of $11.98. Teva Pharmaceutical Industries Limited has a 1 year low of $7.09 and a 1 year high of $17.13. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The stock has a market cap of $18.81 billion, a price-to-earnings ratio of -41.66, a P/E/G ratio of 2.02 and a beta of 1.04.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.